{
  "id": 20589623,
  "title": "Semaglutide may improve eating disorder symptoms and body image in adults seeking obesity treatment",
  "url": "https://urgent.news/2026/11/18/semaglutide-may-improve-eating-disorder-symptoms-and-body-image-in",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-18T12:00:01.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-11-semaglutide-disorder-symptoms-body-image.html"
  },
  "original_language": "en",
  "account": "A recent 60-week study involving 120 adults with obesity and access to lifestyle coaching found that those prescribed semaglutide experienced significant improvements in disordered eating attitudes and behaviors, compared to those receiving a placebo. Led by researchers from the University of Pennsylvania's Perelman School of Medicine, the study, published in the International Journal of Eating Disorders, revealed that semaglutide users lost an average of 15% of their body weight, versus only 3% among placebo recipients. Semaglutide was also linked to greater reductions in binge-eating episodes, overall eating disorder symptoms and negative body image perceptions. Among individuals who began the study with binge eating issues, semaglutide use was associated with a higher likelihood of binge eating cessation. While overall outcomes were positive, the researchers emphasized the need for ongoing monitoring, especially among individuals with a history of eating disorders, as disordered eating behaviors did occur in some cases during the trial.",
  "summary": "Adults receiving semaglutide for obesity treatment experienced greater improvements in several measures of disordered eating, eating disorder symptoms and body image concerns compared with participants receiving placebo, according to a new study led by researchers from the Perelman School of Medicine at the University of Pennsylvania. The study was published in the International Journal of Eating…",
  "key_points": [
    "Semaglutide users lost 15% body weight vs 3% in placebo group",
    "Significant improvements in disordered eating attitudes and behaviors",
    "Higher likelihood of binge eating cessation among initial binge eaters"
  ],
  "editors_take": "The drug's ability to reduce binge-eating episodes and improve body image perceptions suggests that semaglutide could serve as a dual-purpose tool for managing both obesity and disordered eating behaviors.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}